Saturday 17 October 2026
Export IMUX’s income statement to Excel — free account
Immunic, Inc.
IMUX Healthcare Biotechnology
In the quarter to June 2026, EPS grew 60.0% and free cash flow fell 26.8%, each against the same quarter a year earlier.
6.97
0.13
−1.83%
Follow IMUX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(398.50%) | (1,653.15%) | (142.91%) | (138.17%) | |
| (195.41%) | (299.36%) | (99.20%) | (101.15%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(1,047.86%) | 1,360.76% | (69.08%) | (87.61%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(4.62) | (5.52) | (2.70) | (2.07) | |
Free Cash Flow |
(89.64) | (85.97) | (81.45) | (88.05) | |
Capital Expenditures |
(0.15) | (0.16) | (0.12) | (0.33) | |
| Other line items | |||||
Cash ROIC |
(196.45%) | (975.79%) | (24.11%) | (31.15%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.87 | 0.88 | 0.78 | 0.79 | |
Depreciation/Fixed assets |
0.25 | 0.28 | 0.28 | 0.19 | |
Capex/Depreciation |
(0.95) | (0.96) | (0.73) | (2.21) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(4.62) | (5.51) | (2.70) | (2.06) | |
Capex per Share |
(0.01) | (0.01) | 0.00 | (0.01) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates